Account-based marketing: examples that actually work in 2026 for healthcare and life sciences
Real-world account-based marketing plays we have seen produce pipeline this year — the setup, the numbers, and what to copy. Written for commercial leaders at healthtech, medtech, and life-sciences companies.
This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install account-based marketing has to reflect that reality from day one.
Most articles on account-based marketing are five years out of date. This one is not. Account-based marketing in 2026 is concentrating marketing on a named list of accounts with tailored plays, and the examples below are all inside the last four quarters.
Example one: a Series B infrastructure company applied account-based marketing to a list of 340 accounts and moved pipeline created inside the named-account list from a baseline to a defensible weekly number inside seven weeks. What worked was ruthless focus on trigger quality.
Example two: a bootstrapped agency owner ran the same play at one-tenth the budget and produced enough qualified pipeline to hire two full-time operators. The lesson is that account-based marketing scales down, not just up.
The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Account-based marketing is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.
Example three: an enterprise incumbent tried account-based marketing across four regions in parallel and stalled — the exact pattern of confusing ABM with lead scoring on inbound MQLs. They restarted with one BU, hit the number in nine weeks, and then expanded.
The pattern across every winning example: they respect that one enterprise close is worth six mid-market ones, and they refuse to touch the model until they have a legible number on pipeline created inside the named-account list.
The pattern across every failing example: too many tools, too many stakeholders, no single owner. Fix that first and copy the plays.
If you take one thing from this list, it is that account-based marketing is a discipline before it is a technology. The examples that work are all built on the same operating rhythm.
Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing account-based marketing properly rather than half-heartedly across three vendors.
Frequently asked questions
ABM · healthcare — answered
- Does account-based marketing work for healthcare and life sciences?
- Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
- Are there small-team examples of account-based marketing working?
- Yes — the discipline scales down. A single operator with the right list can produce a defensible number.
- How long did the winning examples take to see pipeline created inside the named-account list move?
- Between seven and twelve weeks, consistently, once the trigger and list were tight.
- What did the failing examples get wrong?
- Confusing ABM with lead scoring on inbound MQLs — usually because they scaled before the model was proven.
- Can I copy these plays exactly?
- Copy the operating rhythm and the metric; adapt the triggers and copy to your ICP.
- What is the healthcare specific pitfall with account-based marketing?
- Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.
Growth Broker editorial
Filed under abm · healthcare